CRISPR Therapeutics reported Q2 2024 financial results with a strong cash position of $2 billion as of June 30, 2024. The company has activated more than 35 authorized treatment centers globally for CASGEVY, with approximately 20 patients having cells collected across all regions as of mid-July. CASGEVY is now approved in the US, Great Britain, EU, Saudi Arabia, and Bahrain for both sickle cell disease and transfusion-dependent beta thalassemia.The company continues advancing its pipeline, with clinical trials ongoing for next-generation CAR T products CTX112 and CTX131 across multiple indications. CTX112 trials have expanded into systemic lupus erythematosus, while CTX131 trials now include hematological malignancies. Additionally, in vivo gene editing programs CTX310 and CTX320 targeting cardiovascular diseases are progressing in clinical trials.Q2 financial results showed minimal revenue compared to $70 million in Q2 2023. R&D expenses decreased to $80.2 million from $101.6 million year-over-year. Net loss widened to $126.4 million from $77.7 million in Q2 2023, primarily due to reduced collaboration revenue and increased collaboration expenses related to CASGEVY commercialization.

CRISPR Therapeutics reported Q2 2024 financial results with a strong cash position of $2 billion as of June 30, 2024. The company has activated more than 35 authorized treatment centers globally for CASGEVY, with approximately 20 patients having cells collected across all regions as of mid-July. CASGEVY is now approved in the US, Great Britain, EU, Saudi Arabia, and Bahrain for both sickle cell disease and transfusion-dependent beta thalassemia.The company continues advancing its pipeline, with clinical trials ongoing for next-generation CAR T products CTX112 and CTX131 across multiple indications. CTX112 trials have expanded into systemic lupus erythematosus, while CTX131 trials now include hematological malignancies. Additionally, in vivo gene editing programs CTX310 and CTX320 targeting cardiovascular diseases are progressing in clinical trials.Q2 financial results showed minimal revenue compared to $70 million in Q2 2023. R&D expenses decreased to $80.2 million from $101.6 million year-over-year. Net loss widened to $126.4 million from $77.7 million in Q2 2023, primarily due to reduced collaboration revenue and increased collaboration expenses related to CASGEVY commercialization.